
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Inozyme Pharma Inc (INZY)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: INZY (2-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $4
1 Year Target Price $4
0 | Strong Buy |
0 | Buy |
7 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 50.55% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 258.25M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 7 | Beta 2.29 | 52 Weeks Range 0.72 - 6.24 | Updated Date 07/8/2025 |
52 Weeks Range 0.72 - 6.24 | Updated Date 07/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.68 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -48.45% | Return on Equity (TTM) -141.69% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 220425296 | Price to Sales(TTM) - |
Enterprise Value 220425296 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.25 | Shares Outstanding 64561800 | Shares Floating 29983802 |
Shares Outstanding 64561800 | Shares Floating 29983802 | ||
Percent Insiders 1.26 | Percent Institutions 94.29 |
Upturn AI SWOT
Inozyme Pharma Inc

Company Overview
History and Background
Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases associated with ENPP1 and NT5E deficiencies. Founded in 2015, it went public in 2020. Their focus is on addressing underlying causes, not just symptoms.
Core Business Areas
- Rare Disease Therapeutics: Inozyme focuses on developing therapies targeting ENPP1 and NT5E deficiencies, which lead to serious metabolic and cardiovascular complications.
Leadership and Structure
The leadership team is composed of experienced pharmaceutical executives and scientists. The organizational structure is typical of a clinical-stage biotech company, with departments focused on research, development, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- INZ-701: INZ-701 is a recombinant human ENPP1 enzyme replacement therapy in clinical development for the treatment of ENPP1 deficiency, including Generalized Arterial Calcification of Infancy (GACI) and autosomal recessive hypophosphatemic rickets type 2 (ARHR2). Since this is a new market with no established players for these specific deficiencies, market share is not yet established. Competitors for GACI treatment include symptomatic treatments or experimental therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry is competitive and heavily regulated. The rare disease therapeutics market is growing, driven by increased awareness, orphan drug designations, and unmet medical needs.
Positioning
Inozyme Pharma is positioned as a leader in developing therapies for ENPP1 deficiency. Its competitive advantage lies in its proprietary enzyme replacement therapy and focus on addressing the underlying cause of the disease.
Total Addressable Market (TAM)
The estimated TAM for ENPP1 deficiency related diseases is substantial given the rare nature of the condition. Inozyme is positioned to capture a significant portion of this market if INZ-701 proves effective and receives regulatory approval. TAM estimates are dependent on prevalence and pricing strategies.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Strong intellectual property portfolio
- Experienced management team
- Focus on unmet medical needs
- Orphan drug designation for INZ-701
Weaknesses
- Single clinical-stage product (INZ-701)
- High cash burn rate
- Reliance on successful clinical trial outcomes
- Lack of established revenue streams
- Limited commercial infrastructure
Opportunities
- Expansion of INZ-701 to additional indications
- Partnerships with larger pharmaceutical companies
- Acquisition by a larger pharmaceutical company
- Positive clinical trial results for INZ-701
- Increased awareness of ENPP1 deficiency
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other therapies
- Funding challenges
- Patent disputes
Competitors and Market Share
Key Competitors
- None listed since INZY focuses on ENPP1 deficiency, with no directly competing therapies currently approved.
Competitive Landscape
Since no competing therapies exist, Inozyme holds the competitive advantage with INZ-701 in the rare disease space of ENPP1 deficiency. This advantage is dependent on successful clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily related to R&D spending and clinical trial progress.
Future Projections: Future growth is dependent on the successful development and commercialization of INZ-701. Analyst estimates are based on clinical trial results and market potential. Refer to analyst reports for projections.
Recent Initiatives: Recent initiatives include advancing INZ-701 through clinical trials and seeking regulatory approvals.
Summary
Inozyme Pharma is a clinical-stage biopharmaceutical company focused on rare diseases. Its strength lies in its innovative approach to treating ENPP1 deficiency with INZ-701. However, it faces risks associated with clinical trial outcomes and funding. Successful clinical trials and strategic partnerships are crucial for its growth. Regulatory hurdles pose a continuous challenge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Inozyme Pharma's website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Data may be outdated and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inozyme Pharma Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-07-24 | CEO & Chairman Dr. Douglas A. Treco Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 67 | Website https://www.inozyme.com |
Full time employees 67 | Website https://www.inozyme.com |
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.